Chronic kidney disease: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz No edit summary |
imported>Robert Badgett |
||
| Line 47: | Line 47: | ||
====Aldosterone antagonists==== | ====Aldosterone antagonists==== | ||
[[Aldosterone antagonist]]s may reduce [[proteinuria]] according to a [[systematic review]] by the [[Cochrane Collaboration]].<ref name="pmid19588415">{{cite journal| author=Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF| title=Aldosterone antagonists for preventing the progression of chronic kidney disease. | journal=Cochrane Database Syst Rev | year= 2009 | volume= | issue= 3 | pages= CD007004 | pmid=19588415 | [[Aldosterone antagonist]]s may reduce [[proteinuria]] according to a [[systematic review]] by the [[Cochrane Collaboration]].<ref name="pmid19588415">{{cite journal| author=Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF| title=Aldosterone antagonists for preventing the progression of chronic kidney disease. | journal=Cochrane Database Syst Rev | year= 2009 | volume= | issue= 3 | pages= CD007004 | pmid=19588415 | ||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&email=badgett@uthscdsa.edu&retmode=ref&cmd=prlinks&id=19588415 | doi=10.1002/14651858.CD007004.pub2 }} | | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&email=badgett@uthscdsa.edu&retmode=ref&cmd=prlinks&id=19588415 | doi=10.1002/14651858.CD007004.pub2 }}</ref> | ||
====Angiotensin inhibition==== | ====Angiotensin inhibition==== | ||
| Line 56: | Line 56: | ||
====Secondary hyperparathyroidism==== | ====Secondary hyperparathyroidism==== | ||
[[Clinical practice guideline]]s from the "[http://www.kdigo.org/ Kidney Disease: Improving Global Outcomes (KDIGO)]" address management of [[renal osteodystrophy]].<ref name="pmid16641930">{{cite journal| author=Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K et al.| title=Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). | journal=Kidney Int | year= 2006 | volume= 69 | issue= 11 | pages= 1945-53 | pmid=16641930 | [[Clinical practice guideline]]s from the "[http://www.kdigo.org/ Kidney Disease: Improving Global Outcomes (KDIGO)]" address management of [[renal osteodystrophy]].<ref name="pmid16641930">{{cite journal| author=Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K et al.| title=Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). | journal=Kidney Int | year= 2006 | volume= 69 | issue= 11 | pages= 1945-53 | pmid=16641930 | ||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=16641930 | doi=10.1038/sj.ki.5000414 }} | | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=16641930 | doi=10.1038/sj.ki.5000414 }} [http://www.kdigo.org/clinical_practice_guidelines/kdigo_guideline_for_ckd-mbd.php Free full text]</ref> | ||
* Phosphate binders (calcium carbonate 650 mg tabs three times - Calcichew<sup>™</sup>, Titrala<sup>™</sup>) or calcium acetate (Phosex<sup>™</sup>, PhosLo<sup>™</sup>) per day by mouth. | * Phosphate binders (calcium carbonate 650 mg tabs three times - Calcichew<sup>™</sup>, Titrala<sup>™</sup>) or calcium acetate (Phosex<sup>™</sup>, PhosLo<sup>™</sup>) per day by mouth. | ||
* Vitamin D preparations such as [[calcitriol]] (0.25-0.5 µg orally once per day) or intravenous paricalcitol (Zemplar<sup>™</sup>)are given once a patient has Stage 3 disease in order to prevent secondary [[hyperparathyroidism]]. | * Vitamin D preparations such as [[calcitriol]] (0.25-0.5 µg orally once per day) or intravenous paricalcitol (Zemplar<sup>™</sup>)are given once a patient has Stage 3 disease in order to prevent secondary [[hyperparathyroidism]]. | ||
| Line 63: | Line 63: | ||
====Allopurinol==== | ====Allopurinol==== | ||
A single randomized controlled trial found that giving allopurinol to hyperuricemic patients with chronic kidney disease had a [[relative risk ratio]] of 0.35 in the prevention of "significant deterioration in renal function and dialysis dependence."<ref name="pmid16377385">{{cite journal |author=Siu YP, Leung KT, Tong MK, Kwan TH |title=Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level |journal=Am. J. Kidney Dis. |volume=47 |issue=1 |pages=51–9 |year=2006 |month=January |pmid=16377385 |doi=10.1053/j.ajkd.2005.10.006 |url=http://linkinghub.elsevier.com/retrieve/pii/S0272-6386(05)01518-0 |issn=}}</ref> | A single randomized controlled trial found that giving allopurinol to hyperuricemic patients with chronic kidney disease had a [[relative risk ratio]] of 0.35 in the prevention of "significant deterioration in renal function and dialysis dependence."<ref name="pmid16377385">{{cite journal |author=Siu YP, Leung KT, Tong MK, Kwan TH |title=Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level |journal=Am. J. Kidney Dis. |volume=47 |issue=1 |pages=51–9 |year=2006 |month=January |pmid=16377385 |doi=10.1053/j.ajkd.2005.10.006 |url=http://linkinghub.elsevier.com/retrieve/pii/S0272-6386(05)01518-0 |issn=}}</ref> | ||
===Treatment of associated diseases=== | |||
====Coronary heart disease==== | |||
[[Coronary heart disease]] is common among patients with chronic kidney disease. However: | |||
* Screening for coronary heart disease does not reduce events according to a [[randomized controlled trial]].<ref name="pmid19366774">{{cite journal| author=Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R et al.| title=Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. | journal=JAMA | year= 2009 | volume= 301 | issue= 15 | pages= 1547-55 | pmid=19366774 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19366774 | doi=10.1001/jama.2009.476 | pmc=PMC2895332 }} [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19687481 Review in: Ann Intern Med. 2009 Aug 18;151(4):JC2-7] [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19794012 Review in: Evid Based Med. 2009 Oct;14(5):137] </ref> | |||
====Hypertension==== | |||
* Intensive blood-pressure control had no effect on progression of kidney disease according to a [[randomized controlled trial]]. <ref name="pmid20818902">{{cite journal| author=Appel LJ, Wright JT, Greene T, Agodoa LY, Astor BC, Bakris GL et al.| title=Intensive blood-pressure control in hypertensive chronic kidney disease. | journal=N Engl J Med | year= 2010 | volume= 363 | issue= 10 | pages= 918-29 | pmid=20818902 | doi=10.1056/NEJMoa0910975 }} </ref> | |||
===Renal replacement therapy=== | ===Renal replacement therapy=== | ||
Revision as of 20:24, 22 September 2010
In medicine, chronic kidney disease (CKD) is defined as "kidney damage or glomerular filtration rate (GFR) <60 mL/min/1.73 m(2) for 3 months or more, irrespective of cause. Kidney damage in many kidney diseases can be ascertained by the presence of albuminuria, defined as albumin-to-creatinine ratio >30 mg/g in two of three spot urine specimens."[1]
Classification
There are five stages:[1]
- Stage 1 - glomerular filtration rate is 90 ml/min/1.73 m2 or more
- Stage 2 - glomerular filtration rate is 60-89 ml/min/1.73 m2
- Stage 3 - glomerular filtration rate is 30-59 ml/min/1.73 m2
- Stage 4 - glomerular filtration rate is 15-29 ml/min/1.73 m2
- Stage 5 - glomerular filtration rate is less than 15 ml/min/1.73 m2 or on renal dialysis; also callled end-stage renal disease (ESRD)
Etiology/cause
Bilateral renal artery stenosis (RAS) may cause 5% to 15% of cases of chronic kidney disease.[2]
Prevalence
Thirteen percent of adults in the United States of America have chronic kidney disease as defined by the Kidney Disease Outcomes Quality Initiative (KDOQI).[3] The prevalence is reduced to 11% if isolated microalbuminuria (CKD-1) is not included.[3] However, using otehr criteria, the prevalence is 2.9%.[4]
Routine reporting of the estimated glomerular filtration rate has increased the number of referrals to nephrologists[5]; however, the benefit is uncertain[6].
Signs and symptoms
Uremia, "the illness accompanying kidney failure", may have subtle manifestations when the glomerular filtration rate falls below 60 ml/min/1.73 m2.[7]
Anemia of chronic disease commonly coexists with CKD.
Treatment
The National Kidney Disease Education Program provides guidance on dosing drugs in patients with reduced glomerular filtration rate.[8]
Various drugs have been studied for slowing the progression of chronic kidney disease.[9][10][11]
| Treatment | Setting | Results |
|---|---|---|
| Protein restriction[9] | Diabetic renal disease | relative risk of end stage renal disease or death: |
| Protein restriction[10] | Non-diabetic renal disease | relative risk of renal death: |
| Angiotensin converting enzyme inhibitors[11] | Diabetic renal disease |
Medications
Aldosterone antagonists
Aldosterone antagonists may reduce proteinuria according to a systematic review by the Cochrane Collaboration.[12]
Angiotensin inhibition
Angiotensin can be inhibited with either angiotensin-converting enzyme inhibitors[13] or angiotensin II receptor antagonists. These medications can help patients with an elevated creatinine,[14] including those with a creatinine of 1.5 to 5.0 mg per deciliter.[15]
Combining angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists increases effect, but at uncertain increase in drug toxicity such as hyperkalemia according to a meta-analysis.[16] Adding an aldosterone receptor antagonist such as spironolactone may add further benefit, but presumably more hyperkalemia.[17]
Secondary hyperparathyroidism
Clinical practice guidelines from the "Kidney Disease: Improving Global Outcomes (KDIGO)" address management of renal osteodystrophy.[18]
- Phosphate binders (calcium carbonate 650 mg tabs three times - Calcichew™, Titrala™) or calcium acetate (Phosex™, PhosLo™) per day by mouth.
- Vitamin D preparations such as calcitriol (0.25-0.5 µg orally once per day) or intravenous paricalcitol (Zemplar™)are given once a patient has Stage 3 disease in order to prevent secondary hyperparathyroidism.
- Calcimimetic such as cinacalcet (Sensipar™) may help.
Allopurinol
A single randomized controlled trial found that giving allopurinol to hyperuricemic patients with chronic kidney disease had a relative risk ratio of 0.35 in the prevention of "significant deterioration in renal function and dialysis dependence."[19]
Treatment of associated diseases
Coronary heart disease
Coronary heart disease is common among patients with chronic kidney disease. However:
- Screening for coronary heart disease does not reduce events according to a randomized controlled trial.[20]
Hypertension
- Intensive blood-pressure control had no effect on progression of kidney disease according to a randomized controlled trial. [21]
Renal replacement therapy
Prognosis
The estimated glomerular filtration rate and the urinary albumin/creatinine ratio can help predict who will progress to CKD5.[22]
References
- ↑ 1.0 1.1 Levey AS, Eckardt KU, Tsukamoto Y, et al (2005). "Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)". Kidney Int. 67 (6): 2089–100. DOI:10.1111/j.1523-1755.2005.00365.x. PMID 15882252. Research Blogging.
- ↑ Rimmer JM, Gennari FJ (May 1993). "Atherosclerotic renovascular disease and progressive renal failure". Ann. Intern. Med. 118 (9): 712–9. PMID 8460859. [e]
- ↑ 3.0 3.1 Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P et al. (2007). "Prevalence of chronic kidney disease in the United States.". JAMA 298 (17): 2038-47. DOI:10.1001/jama.298.17.2038. PMID 17986697. Research Blogging.
- ↑ Rutkowski M, Mann W, Derose S, Selevan D, Pascual N, Diesto J et al. (2009). "Implementing KDOQI CKD definition and staging guidelines in Southern California Kaiser Permanente.". Am J Kidney Dis 53 (3 Suppl 3): S86-99. DOI:10.1053/j.ajkd.2008.07.052. PMID 19231766. Research Blogging.
- ↑ Hemmelgarn BR, Zhang J, Manns BJ, James MT, Quinn RR, Ravani P et al. (2010). "Nephrology visits and health care resource use before and after reporting estimated glomerular filtration rate.". JAMA 303 (12): 1151-8. DOI:10.1001/jama.2010.303. PMID 20332400. Research Blogging.
- ↑ den Hartog JR, Reese PP, Cizman B, Feldman HI (2009). "The costs and benefits of automatic estimated glomerular filtration rate reporting.". Clin J Am Soc Nephrol 4 (2): 419-27. DOI:10.2215/CJN.04080808. PMID 19176794. PMC PMC2637597. Research Blogging.
- ↑ Meyer TW, Hostetter TH (2007). "Uremia.". N Engl J Med 357 (13): 1316-25. DOI:10.1056/NEJMra071313. PMID 17898101. Research Blogging.
- ↑ The National Kidney Disease Education Program. (2009) Chronic Kidney Disease and Drug Dosing: Information for Providers National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), U.S. Department of Health & Human Services (DHHS).
- ↑ 9.0 9.1 Robertson L, Waugh N, Robertson A (2007). "Protein restriction for diabetic renal disease". Cochrane Database Syst Rev (4): CD002181. DOI:10.1002/14651858.CD002181.pub2. PMID 17943769. Research Blogging.
- ↑ 10.0 10.1 Fouque D, Laville M, Boissel JP (2006). "Low protein diets for chronic kidney disease in non diabetic adults". Cochrane Database Syst Rev (2): CD001892. DOI:10.1002/14651858.CD001892.pub2. PMID 16625550. Research Blogging.
- ↑ 11.0 11.1 Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC (2006). "Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease". Cochrane Database Syst Rev (4): CD006257. DOI:10.1002/14651858.CD006257. PMID 17054288. Research Blogging.
- ↑ Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF (2009). "Aldosterone antagonists for preventing the progression of chronic kidney disease.". Cochrane Database Syst Rev (3): CD007004. DOI:10.1002/14651858.CD007004.pub2. PMID 19588415. Research Blogging.
- ↑ Jafar TH, Stark PC, Schmid CH, et al (2003). "Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis". Ann. Intern. Med. 139 (4): 244–52. PMID 12965979. [e]
- ↑ Ruggenenti P, Perna A, Remuzzi G (2001). "ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy". J. Am. Soc. Nephrol. 12 (12): 2832–7. PMID 11729254. [e]
- ↑ Hou FF, Zhang X, Zhang GH, et al (2006). "Efficacy and safety of benazepril for advanced chronic renal insufficiency". N. Engl. J. Med. 354 (2): 131–40. DOI:10.1056/NEJMoa053107. PMID 16407508. Research Blogging.
- ↑ Kunz R, Friedrich C, Wolbers M, Mann JF (January 2008). "Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease". Ann. Intern. Med. 148 (1): 30–48. PMID 17984482. [e]
- ↑ Tylicki L, Rutkowski P, Renke M, et al (September 2008). "Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial". Am. J. Kidney Dis. 52 (3): 486–93. DOI:10.1053/j.ajkd.2008.02.297. PMID 18423812. Research Blogging.
- ↑ Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K et al. (2006). "Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).". Kidney Int 69 (11): 1945-53. DOI:10.1038/sj.ki.5000414. PMID 16641930. Research Blogging. Free full text
- ↑ Siu YP, Leung KT, Tong MK, Kwan TH (January 2006). "Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level". Am. J. Kidney Dis. 47 (1): 51–9. DOI:10.1053/j.ajkd.2005.10.006. PMID 16377385. Research Blogging.
- ↑ Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R et al. (2009). "Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial.". JAMA 301 (15): 1547-55. DOI:10.1001/jama.2009.476. PMID 19366774. PMC PMC2895332. Research Blogging. Review in: Ann Intern Med. 2009 Aug 18;151(4):JC2-7 Review in: Evid Based Med. 2009 Oct;14(5):137
- ↑ Appel LJ, Wright JT, Greene T, Agodoa LY, Astor BC, Bakris GL et al. (2010). "Intensive blood-pressure control in hypertensive chronic kidney disease.". N Engl J Med 363 (10): 918-29. DOI:10.1056/NEJMoa0910975. PMID 20818902. Research Blogging.
- ↑ Hallan SI, Ritz E, Lydersen S, Romundstad S, Kvenild K, Orth SR (April 2009). "Combining GFR and Albuminuria to Classify CKD Improves Prediction of ESRD". J. Am. Soc. Nephrol.. DOI:10.1681/ASN.2008070730. PMID 19357254. Research Blogging.